VIVO Meridian Bioscience Inc.

MERIDIAN BIOSCIENCE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Meridian Bioscience, Inc. – VIVO

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Meridian Bioscience, Inc. (NasdaqGS: VIVO).

On January 25, 2017, the Company revealed negative 1Q2017 financial results, reducing revenue guidance for the fiscal year and a reduction to the annual indicated dividend rate. Then, on May 17, 2017, a safety notice was issued by the U.S. Food and Drug Administration (“FDA”) advising that consumers halt the use of the Company’s lead poisoning testing system due to a product recall. Then, on October 23, 2017, the Company was issued a warning letter from the FDA, which was explained by the FDA in its accompanying press release was the result of “several violations of federal law” including “marketing significantly modified versions of two of its blood lead testing systems without the FDA’s required clearance or approval and failing to submit medical device reports to the FDA after becoming aware of customer complaints involving discrepancies in blood lead test results.” Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit for failing to disclose material information, violating federal securities laws.

KSF’s investigation focuses on whether Meridian’s officers and/or directors breached their fiduciary duties to Meridian’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Meridian shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]).

About Kahn Swick & Foti, LLC

KSF, whose partners include Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

EN
06/01/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Meridian Bioscience Inc.

 PRESS RELEASE

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detec...

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Stool Samples CINCINNATI, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the addition of two new Air-Dryable™ Master Mixes with the launch of its Air-Dryable™ Direct DNA qPCR Stool and Air-Dryable™ Direct RNA/DNA qPCR Stool Mixes. These innovative master mixes are designed to develop room-temperature stable molecular diagnostic assays that directly target nucleic acid sequences...

 PRESS RELEASE

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detec...

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples CINCINNATI, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva Mixes, which are designed for incorporation in room-temperature stable molecular assays, directly targeting nucleic acid sequence from saliva and sputum. Saliva is a complex fluid containing various enzy...

 PRESS RELEASE

Meridian Bioscience Reports Third Quarter Fiscal 2021 Results

Meridian Bioscience Reports Third Quarter Fiscal 2021 Results CINCINNATI, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2021. Third Quarter 2021 Highlights (Comparison to Third Quarter Fiscal 2020):• Consolidated net revenues of $63.5 million, down 25% year-over-year, but up 31% from pre-pandemic third quarter fiscal 2019• Diagnostics segment net revenues increased 44% year-over-year to $31.2 million• Life Science segment net revenues decreased 49% year-over-year to $32.3 million• Re-Submi...

 PRESS RELEASE

Meridian Closes Acquisition of BreathTek® Business

Meridian Closes Acquisition of BreathTek® Business CINCINNATI, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the previously announced acquisition of the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. effective July 31, 2021. Information on the financial impacts to Meridian’s fiscal fourth quarter will be discussed on the quarterly earnings call scheduled for Friday, August 6, 2021. About Meridian Bioscience, Inc.Meridian is ...

 PRESS RELEASE

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H....

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc. CINCINNATI, July 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. for $20 million in cash. The transaction is expected to close in Meridian’s fiscal fourth quarter. With this acquisition, Meridian will assume the customer relationshi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch